Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870671 · ClinicalTrials.gov registry record · Early Phase 1
Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor
A Early Phase 1 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT04870671 is a Early Phase 1 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 14 participants.
The verdict
NCT04870671, a Early Phase 1 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for pre-exposure prophylaxis (PrEP) in women exposed to high HIV risk through vaginal acquisition. Adherence to the one pill per day regimen is crucial for its effectiveness in reducing the risk of acquiring HIV. Currently, there is no available point of care diagnostic test to quickly measure blood levels of tenofovir in the clinic. This study will determine whether a tenofovir (TFV) aptamer-based biosensor (aptasensor) can detect TFV in biological fluids from women randomized to different dosing regimens representing high and low adherence.
Interventions
- DRUG Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-03-25 |
| Est. Completion | 2023-01-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04870671
The ClinicalTrials.gov registry entry for NCT04870671 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) is the first listed.
NCT04870671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04870671 about?
NCT04870671 is a clinical study titled "Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor". Truvada®, an oral pill comprised of two anti-retroviral compounds, emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), is currently the only drug combination approved for pre-exposure prophylaxis (PrEP) in women exposed to high HIV risk through vaginal acquisition. Adherence to the one pill...
What is the current status of trial NCT04870671?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2021-03-25. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT04870671?
The interventions under investigation include: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) (DRUG).
Who is sponsoring clinical trial NCT04870671?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.